Year archive

Lytix Biopharma AS — 2024 filings

All 65 regulatory filings released by Lytix Biopharma AS (LYTIX) in 2024, sourced directly from the official regulator.

65 Filings

2024 Period

2024 filings (65)

Filing	Released	Lang
Lytix Biopharma presents updated phase II results from skin cancer study (BCC) at the DNB Nordic Healthcare Conference Investor Presentation	2024-11-26	English
Lytix Biopharma presents updated phase II results from skin cancer study (BCC) at the DNB Nordic Healthcare Conference Regulatory Filings	2024-11-26	English
Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion Share Issue/Capital Change	2024-11-21	English
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization Earnings Release Q3 2024	2024-11-19	English
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization Investor Presentation	2024-11-19	English
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization Earnings Release Q3 2024	2024-11-19	English
Lytix Biopharma: Invitation to Q3 2024 Results Presentation Report Publication Announcement	2024-11-12	English
Lytix Biopharma: Invitation to Q3 2024 Results Presentation Report Publication Announcement	2024-11-12	English
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma Regulatory Filings	2024-11-06	English
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma Regulatory Filings	2024-11-06	English
Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals Legal Proceedings Report	2024-11-05	Norwegian
Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals M&A Activity	2024-11-05	English
Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals Report Publication Announcement	2024-11-05	Norwegian
Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals Earnings Release Q3 2024	2024-11-05	English
Financial calendar Report Publication Announcement	2024-11-01	English
Finansiell kalender Report Publication Announcement	2024-11-01	Norwegian
Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference Investor Presentation	2024-10-24	English
Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference Earnings Release H1 2025	2024-10-24	English
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization Earnings Release H1 2024	2024-08-29	English
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization Investor Presentation H1 2024	2024-08-29	English
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization Interim / Quarterly Report H1 2024	2024-08-29	English
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization Earnings Release H1 2024	2024-08-29	English
Lytix Biopharma: Invitation to Q2 2024 Results Presentation Report Publication Announcement	2024-08-23	English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones Investor Presentation	2024-05-30	English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones Earnings Release Q1 2024	2024-05-30	English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones Earnings Release Q1 2024	2024-05-30	English
Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 Report Publication Announcement	2024-05-22	English
Lytix Biopharma – Minutes of Ordinary General Meeting AGM Information	2024-05-14	Norwegian
Lytix Biopharma – Minutes of Ordinary General Meeting AGM Information	2024-05-14	English
LYTIX BIOPHARMA AS - NEW SHARE CAPITAL REGISTERED Share Issue/Capital Change	2024-05-13	English
Correction in the notice of Annual General Meeting in Lytix Biopharma AS AGM Information	2024-05-03	English
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024 AGM Information	2024-04-30	Norwegian
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024 AGM Information	2024-04-30	English
Lytix Biopharma AS: Annual Report for 2023 Annual Report FY 2023	2024-04-30	English
Lytix Biopharma AS: Annual Report for 2023 Report Publication Announcement	2024-04-30	English
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS AND CLOSE ASSOCIATES Director's Dealing	2024-04-26	English
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS AND CLOSE ASSOCIATES Director's Dealing	2024-04-26	English
LYTIX BIOPHARMA AS – SHARE ISSUE PURSUANT TO BOARD AUTHORIZATION Capital/Financing Update	2024-04-26	English
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates Director's Dealing	2024-04-25	English
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates Share Issue/Capital Change	2024-04-25	English
LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING AGM Information	2024-04-25	Norwegian
LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING AGM Information	2024-04-25	English
Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet Regulatory Filings	2024-04-25	Norwegian
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity. Regulatory Filings	2024-04-25	English
LYTIX BIOPHARMA AS – PRELIMINARY RESULTS IN THE SHARE OFFERING Share Issue/Capital Change	2024-04-24	English
Lytix Biopharma AS - Last day of the Application Period Share Issue/Capital Change	2024-04-24	English
Lytix Biopharma AS – Ex Date Share Issue/Capital Change	2024-04-12	English
Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling Capital/Financing Update	2024-04-10	Norwegian
Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024 AGM Information	2024-04-10	Norwegian
Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024 Capital/Financing Update	2024-04-10	English
Lytix Biopharma AS – Publication of Prospectus and commencement of Application Period Report Publication Announcement	2024-04-10	English
Lytix Biopharma AS - Key information relating to the share offer Capital/Financing Update	2024-04-09	English
Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders – several key milestones coming up with large commercial potential Share Issue/Capital Change	2024-04-09	English
LYTIX BIOPHARMA AS: Contemplated Offering Share Issue/Capital Change	2024-04-09	English
Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous Regulatory Filings	2024-04-02	English
Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous Regulatory Filings	2024-04-02	English
Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways Regulatory Filings	2024-03-21	English
Financial calendar Report Publication Announcement	2024-03-20	English
Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients Investor Presentation	2024-02-29	English
Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients Earnings Release FY 2023	2024-02-29	English
Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients Earnings Release Q4 2023	2024-02-29	English
Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients Report Publication Announcement Q4 2023	2024-02-29	English
Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2023 results, Thursday 29 February 2024 Earnings Release Q4 2023	2024-02-22	English
Financial calendar Regulatory Filings	2024-01-26	English
Lytix Biopharma presenting at Redeye Fight Cancer Event 2024 Report Publication Announcement	2024-01-23	English